Therapy of cancer metastasis by tumoricidal activation of tissue macrophages using liposome-encapsulated immunomodulators

被引:48
作者
Killion, JJ [1 ]
Fidler, IJ [1 ]
机构
[1] Univ Texas, MD Anderson Cancer Ctr, Dept Cell Biol, Houston, TX 77030 USA
关键词
macrophage activation; metastasis; immunomodulators; muramyl tripeptide; liposomes;
D O I
10.1016/S0163-7258(98)00004-7
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The therapy of cancer requires strategies that can eradicate metastatic disease. Metastases consist of unique subpopulations of tumor cells that are able to colonize distant organs and become autonomous from homeostatic mechanisms. Conventional therapies generally have been unsuccessful due to biological heterogeneity in metastatic tumors. It is possible to circumvent this heterogeneity by the tumoricidal activation of tissue macrophages. Activation can be achieved by encapsulation of immunomodulators, e.g., muramyl tripeptide analogues, into liposomes, and this form of immunomodulation leads to eradication of established tumor metastases in numerous animal tumor models. Modulation of the tumor microenvironment by activated macrophages may prove to be an additional modality in therapy that combines the use of biological response modifiers with conventional therapies. (C) 1998 Elsevier Science Inc.
引用
收藏
页码:141 / 154
页数:14
相关论文
共 135 条
[71]  
KILLION JJ, 1989, SEMIN ONCOL, V16, P106
[72]   ISOLATION OF IMMUNOGENIC TUMOR-CELLS BY CELL-AFFINITY CHROMATOGRAPHY [J].
KILLION, JJ ;
KOLLMORGEN, GM .
NATURE, 1976, 259 (5545) :674-676
[73]  
KILLION JJ, 1992, ONCOL RES, V4, P413
[74]   IMMUNOTHERAPY WITH TUMOR-CELL SUB-POPULATIONS .2. THERAPY OF DRUG-RESISTANT L1210-LEUKEMIA AND EL4-LYMPHOMA [J].
KILLION, JJ .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 1978, 5 (01) :21-26
[75]   Maintenance of intestinal epithelium structural integrity and mucosal leukocytes during chemotherapy by oral administration of muramyl tripeptide phosphatidylethanolamine [J].
Killion, JJ ;
Bucana, CD ;
Radinsky, R ;
Dong, ZY ;
OReilly, T ;
Bilbe, G ;
Tarcsay, L ;
Fidler, IJ .
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 1996, 11 (06) :363-371
[76]  
KILLION JJ, 1997, LUNG MACROPHAGES DEN, P693
[77]  
Kleinerman E S, 1983, Lymphokine Res, V2, P7
[78]   COMBINATION THERAPY WITH IFOSFAMIDE AND LIPOSOME-ENCAPSULATED MURAMYL TRIPEPTIDE - TOLERABILITY, TOXICITY, AND IMMUNE STIMULATION [J].
KLEINERMAN, ES ;
MEYERS, PA ;
RAYMOND, AK ;
GANO, JB ;
JIA, SF ;
JAFFE, N .
JOURNAL OF IMMUNOTHERAPY, 1995, 17 (03) :181-193
[79]  
KLEINERMAN ES, 1983, CANCER RES, V43, P2010
[80]   UNIQUE HISTOLOGICAL-CHANGES IN LUNG METASTASES OF OSTEOSARCOMA PATIENTS FOLLOWING THERAPY WITH LIPOSOMAL MURAMYL TRIPEPTIDE (CGP-19835A LIPID) [J].
KLEINERMAN, ES ;
RAYMOND, AK ;
BUCANA, CD ;
JAFFE, N ;
HARRIS, MB ;
KRAKOFF, IH ;
BENJAMIN, R ;
FIDLER, IJ .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 1992, 34 (04) :211-220